These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31734445)

  • 1. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours.
    Debie P; Lafont C; Defrise M; Hansen I; van Willigen DM; van Leeuwen FWB; Gijsbers R; D'Huyvetter M; Devoogdt N; Lahoutte T; Mollard P; Hernot S
    J Control Release; 2020 Jan; 317():34-42. PubMed ID: 31734445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies.
    Beltrán Hernández I; Rompen R; Rossin R; Xenaki KT; Katrukha EA; Nicolay K; van Bergen En Henegouwen P; Grüll H; Oliveira S
    Mol Imaging Biol; 2019 Dec; 21(6):1079-1088. PubMed ID: 30859470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
    Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
    Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
    Erreni M; D'Autilia F; Avigni R; Bolli E; Arnouk SM; Movahedi K; Debie P; Anselmo A; Parente R; Vincke C; van Leeuwen FWB; Allavena P; Garlanda C; Mantovani A; Doni A; Hernot S; Van Ginderachter JA
    Theranostics; 2023; 13(1):355-373. PubMed ID: 36593955
    [No Abstract]   [Full Text] [Related]  

  • 13. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
    McLarty K; Cornelissen B; Scollard DA; Done SJ; Chun K; Reilly RM
    Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):81-93. PubMed ID: 18712381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
    Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
    Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
    Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
    Eur J Pharm Biopharm; 2019 Jan; 134():37-48. PubMed ID: 30408518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
    Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP
    Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.